Get the Stockscreener App
293.73
1.87%
5.39
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $293.73, with a volume of 620.26K.
It is up +1.87% in the last 24 hours and up +9.85% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$288.34
Open:
$288.21
24h Volume:
620.26K
Relative Volume:
0.70
Market Cap:
$43.01B
Revenue:
$5.15B
Net Income/Loss:
$1.40B
P/E Ratio:
30.89
EPS:
9.51
Net Cash Flow:
$1.65B
1W Performance:
+3.10%
1M Performance:
+9.85%
6M Performance:
+26.78%
1Y Performance:
+31.48%
1-Day Range:
$288.21
$293.81
1-Week Range:
$283.91
$293.81
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Updates Dividend Exchange Rate for ASX CDI Holders - MSN
Resmed names new board director - HME News
Stock Analysis | ResMed OutlookTechnical Weakness Weighs Despite Strong Fundamentals - AInvest
ResMed up on bullish analyst notes after solid quarter - MSN
Resmed Director Makes a Significant Stock Sale! - TipRanks
Buy ResMed and this ASX stock for 10%+ returns - MSN
Resmed director Hernandez sells $739k in stock - Investing.com
Resmed Inc Announces Proposed Sale of Securities - TipRanks
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - Koreabizwire
Resmed Elects Nicole Mowad-Nassar to Board of Directors, Announces Retirement of Rich Sulpizio - Quiver Quantitative
Resmed announces election of Nicole Mowad-Nassar to board, upcoming retirement of Rich Sulpizio - MarketScreener
Resmed, Inc. - Via Ritzau
CICC Adjusts Price Target on ResMed to $325 From $295, Maintains Outperform Rating - MarketScreener
Is ResMed Inc. forming higher highs and higher lowsIndex Update & Target Return Focused Stock Picks - thegnnews.com
Why ResMed Inc. stock attracts strong analyst attentionWeekly Risk Report & Growth Focused Investment Plans - thegnnews.com
Are Resmed CDI (ASX:RMD) shares good value in 2025? - Rask Media
What’s the analyst consensus on ResMed Inc.July 2025 Trade Ideas & Verified Technical Signals - newsyoung.net
ResMed Gains 0.06% as $290M Volume Ranks 357th Mixed Institutional and Analyst Signals Fuel Market Uncertainty - AInvest
22% Of This ResMed Insider's Holdings Were Sold - 富途牛牛
ResMed Shares Dip 1.23% as Daily Volume Ranks 381st Amid Market Volatility - AInvest
ResMed’s (RMD) Dividend Hike and Buybacks Could Be a Game Changer for Investor Sentiment - simplywall.st
ResMed Inc. Price Targets Raised After Rebound2025 Major Catalysts & Safe Entry Momentum Tips - beatles.ru
ResMed Inc.’s Price Action Aligns with Quant SignalsJuly 2025 Opening Moves & AI Driven Price Forecasts - sundaytimes.kr
Sector Leaders Rotate Capital Into ResMed Inc.Portfolio Risk Report & Accurate Entry/Exit Alerts - 선데이타임즈
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
The Top 5 Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
Can ResMed Inc. disrupt its industryLow Risk High Return Picks - thegnnews.com
Ex-Dividend Reminder: WEC Energy Group, UNITIL and ResMed - Nasdaq
Are Bears Losing Grip on ResMed Inc.Entry Zone Strategy for Consistent Profit Shared - beatles.ru
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - sharewise.com
ResMed Rises to 432nd in Market Activity Amid 13.1% Earnings Growth Outlook and $0.24 Billion Volume - AInvest
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago - MSN
ResMed Insider Sold Shares Worth $2,238,379, According to a Recent SEC Filing - MarketScreener
Resmed Earnings Up 10% in FY2025 - San Diego Business Journal
ResMed Full Year 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Is ResMed's (RMD) Dividend Hike and Leadership Change Shaping Its Capital Allocation Strategy? - simplywall.st
Dividend Information on ResMed: Essential Details Before the Ex-Dividend Date on Aug 14, 2025 - AInvest
ResMed: Accelerating Global Expansion With Strong Growth in Europe & China! - Smartkarma
ResMed’s 419th High-Volume Rank Drives 166.71% Gains as Liquidity-Driven Strategy Surpasses Benchmark - AInvest
RESMED INC SEC 10-K Report - TradingView
ResMed CEO Sells Shares - MarketScreener
ResMed Inc. Reports Change in Beneficial Ownership - TipRanks
ResMed CFO Adjusts Stock Holdings in Routine Transaction - TipRanks
ResMed Ranks 453rd in $260M Volume as Institutional Buys and Earnings Beat Fuel Analyst Price Hikes - AInvest
Macro Intelligence: ResMed breathes easy with FY2025 financial growth - ig.com
ResMed Stock Slides on 39.59% Volume Drop to $280M Ranks 425th as Analysts Hike Targets to $290-$325 Amid Strong Earnings and Dividend Boost - AInvest
ResMed is an ASX share market success story that deserves your attention - MSN
Morgans Maintains Buy Rating for Resmed Inc with Price Target of A$47.86 - AInvest
Resmed Inc Reports Increase in CHESS Depositary Interests - TipRanks
ResMed Inc Announces Proposed Sale of Common Shares - MSN
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):